Jukka Mustonen Selected Research

Hantavirus Infections

1/2022	Increased Heparanase Levels in Urine during Acute Puumala Orthohantavirus Infection Are Associated with Disease Severity.
1/2022	Neutralizing Antibody Titers in Hospitalized Patients with Acute Puumala Orthohantavirus Infection Do Not Associate with Disease Severity.
12/2021	Severity Biomarkers in Puumala Hantavirus Infection.
11/2021	ABO and Rhesus Blood Groups in Acute Puumala Hantavirus Infection.
1/2021	Heterologous boosting of nonrelated toxoid immunity during acute Puumala hantavirus infection.
1/2021	Hormonal Defects Are Common during Puumala Hantavirus Infection and Associate with Disease Severity and Biomarkers of Altered Haemostasis.
11/2019	Interleukin 34 in hantavirus infection.
1/2019	Urine and Free Immunoglobulin Light Chains as Analytes for Serodiagnosis of Hantavirus Infection.
1/2019	Glycoprotein YKL-40 Is Elevated and Predicts Disease Severity in Puumala Hantavirus Infection.
1/2017	Indoleamine 2,3-dioxygenase activity is associated with regulatory T cell response in acute Puumala hantavirus infection.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jukka Mustonen Research Topics

Disease

23	Hantavirus Infections 01/2022 - 10/2003
22	Infections 12/2021 - 09/2002
12	Hemorrhagic Fever with Renal Syndrome (HFRS) 12/2021 - 10/2004
12	Inflammation (Inflammations) 01/2021 - 03/2002
8	IGA Glomerulonephritis (IGA Nephropathy) 05/2021 - 03/2002
8	Thrombocytopenia (Thrombopenia) 01/2021 - 08/2010
8	Hypertension (High Blood Pressure) 01/2021 - 12/2006
6	Chronic Renal Insufficiency 01/2020 - 01/2012
4	Essential Hypertension 01/2022 - 01/2019
4	Proteinuria 01/2022 - 05/2004
4	Celiac Disease (Celiac Sprue) 05/2021 - 10/2002
4	Insulin Resistance 01/2019 - 03/2007
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 09/2006
4	Renal Insufficiency (Renal Failure) 03/2015 - 01/2008
4	Kidney Diseases (Kidney Disease) 01/2015 - 07/2009
3	Convalescence 01/2021 - 01/2013
3	Acute Kidney Injury (Acute Renal Failure) 01/2021 - 01/2012
3	Atherosclerosis 12/2019 - 01/2019
3	Glomerulonephritis 01/2008 - 02/2003
2	Disseminated Intravascular Coagulation 01/2021 - 08/2010
2	Thrombosis (Thrombus) 01/2021 - 08/2010
2	Fever (Fevers) 07/2020 - 08/2010
2	Interstitial Nephritis (Tubulointerstitial Nephritis) 10/2019 - 10/2017
2	Atrophy 10/2017 - 01/2005
2	Hyperuricemia 03/2015 - 09/2009
2	Leukocytosis (Pleocytosis) 11/2014 - 01/2012
2	Necrosis 01/2009 - 01/2008
2	Nephritis 09/2006 - 05/2004
2	Rheumatoid Arthritis 09/2006 - 11/2005
1	Disease Susceptibility (Diathesis) 11/2021
1	Hypotension (Low Blood Pressure) 11/2021
1	Whooping Cough (Pertussis) 01/2021
1	Diphtheria 01/2021
1	Tetanus 01/2021
1	Hyperaldosteronism (Conn Syndrome) 11/2020

Drug/Important Bio-Agent (IBA)

8	CreatinineIBA 10/2017 - 11/2004
6	Immunoglobulin A (IgA)IBA 05/2021 - 06/2005
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2009
5	AntigensIBA 01/2021 - 07/2009
5	Uric Acid (Urate)IBA 01/2019 - 01/2005
4	Antihypertensive Agents (Antihypertensives)IBA 01/2022 - 01/2016
4	Biomarkers (Surrogate Marker)IBA 12/2021 - 01/2009
4	Triglycerides (Triacylglycerol)IBA 01/2019 - 01/2005
4	C-Reactive ProteinIBA 01/2019 - 04/2008
4	Interleukin-6 (Interleukin 6)IBA 01/2009 - 03/2002
4	Immunoglobulin M (IgM)IBA 01/2006 - 02/2003
3	Protein Glutamine gamma Glutamyltransferase 2IBA 05/2021 - 01/2018
3	Immunoglobulin G (IgG)IBA 01/2021 - 11/2005
3	CytokinesIBA 01/2021 - 03/2002
3	AntibodiesIBA 01/2021 - 07/2009
3	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 05/2014
3	CalciumIBA 01/2020 - 01/2014
3	Serum AlbuminIBA 09/2019 - 04/2008
3	Glycoproteins (Glycoprotein)IBA 01/2019 - 01/2013
3	HDL CholesterolIBA 01/2019 - 05/2014
3	icatibantIBA 02/2015 - 06/2013
3	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 05/2014 - 03/2002
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2009 - 03/2002
2	Dacarbazine (DIC)FDA LinkGeneric 01/2021 - 08/2010
2	Hormones (Hormone)IBA 01/2021 - 01/2016
2	Antiviral Agents (Antivirals)IBA 01/2021 - 09/2002
2	ReninIBA 11/2020 - 10/2017
2	AlbuminsIBA 07/2020 - 11/2004
2	Adenine FDA LinkGeneric 01/2020 - 10/2017
2	InterleukinsIBA 11/2019 - 01/2008
2	oxidized low density lipoproteinIBA 01/2019 - 01/2019
2	LDL CholesterolIBA 01/2019 - 01/2019
2	Plasminogen Activator Inhibitor 1IBA 02/2018 - 05/2012
2	Plasminogen InactivatorsIBA 02/2018 - 05/2014
2	Histones (Histone)IBA 01/2018 - 11/2014
2	Prothrombin (Factor II)IBA 12/2016 - 08/2010
2	fibrin fragment D (D-dimer)IBA 12/2016 - 08/2010
2	Messenger RNA (mRNA)IBA 03/2015 - 01/2012
2	Vasoconstrictor AgentsIBA 03/2015 - 12/2006
2	Oxonic AcidIBA 03/2015 - 09/2009
2	Bradykinin Receptor AntagonistsIBA 11/2014 - 06/2013
2	Cystatin CIBA 10/2014 - 03/2007
2	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2014 - 11/2004
2	EnzymesIBA 01/2013 - 11/2004
2	paricalcitol (Zemplar)FDA Link 01/2012 - 01/2008
2	Fibrinogen (Factor I)FDA Link 09/2011 - 08/2010
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2008 - 10/2004
1	Monoclonal AntibodiesIBA 01/2022
1	Neutralizing AntibodiesIBA 01/2022
1	N 30IBA 01/2022
1	Immune Sera (Antisera)IBA 01/2022
1	heparanaseIBA 01/2022
1	Blood Group Antigens (Blood Groups)IBA 11/2021
1	AutoantibodiesIBA 05/2021
1	Glutens (Glutelin)IBA 05/2021
1	Parathyroid Hormone (Parathormone)IBA 01/2021
1	VaccinesIBA 01/2021
1	ToxoidsIBA 01/2021
1	HLA-DR Antigens (HLA-DR)IBA 01/2021
1	Chemokine ReceptorsIBA 01/2021
1	AldosteroneIBA 11/2020

Therapy/Procedure

5	Therapeutics 01/2022 - 09/2006
2	Length of Stay 01/2021 - 09/2019
2	Nephrectomy 01/2020 - 01/2012
1	Gluten-Free Diet 05/2021